Holen Sie sich die Stockscreener-App
0.413
0.98%
0.004
Handel nachbörslich:
.39
-0.023
-5.57%
Schlusskurs vom Vortag:
$0.409
Offen:
$0.3882
24-Stunden-Volumen:
335.50K
Relative Volume:
0.94
Marktkapitalisierung:
$1.50M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.28M
KGV:
-0.1372
EPS:
-3.01
Netto-Cashflow:
$-9.78M
1W Leistung:
-10.02%
1M Leistung:
-54.37%
6M Leistung:
-80.24%
1J Leistung:
-93.20%
1-Tages-Spanne:
$0.3688
$0.413
1-Wochen-Bereich:
$0.3688
$0.66
52-Wochen-Spanne:
$0.3688
$6.19
Ensysce Biosciences Inc Stock (ENSC) Company Profile
Firmenname
Ensysce Biosciences Inc
Sektor
Branche
Telefon
(858) 263-4196
Adresse
7946 IVANHOE AVENUE, LA JOLLA
Compare ENSC vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
0.413 | 1.49M | 0 | -11.28M | -9.78M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Ensysce Biosciences Inc Aktie (ENSC) Neueste Nachrichten
RSI Check: Will Ensysce Biosciences Inc benefit from geopolitical trends2025 Trading Volume Trends & Weekly Sector Rotation Insights - baoquankhu1.vn
Ensysce Biosciences Reaches 50% Enrollment Milestone In Pivotal Phase 3 Trial Of PF614 - Nasdaq
Ensysce Biosciences reaches 50% enrollment in Phase 3 pain drug trial - Investing.com Nigeria
Does Ensysce Biosciences Inc. meet Warren Buffett’s criteriaEarnings Risk Summary & Capital Efficient Trade Techniques - mfd.ru
Ensysce Biosciences CEO says 'positioned for continued momentum' - MSN
Ensysce Biosciences reaches 50% enrollment in Phase 3 pain drug trial By Investing.com - Investing.com South Africa
New Highs: Does JPMPRM outperform in volatile marketsTrade Volume Report & Stock Timing and Entry Methods - baoquankhu1.vn
Chronic and Acute Pain Clinical Trial Pipeline Analysis: 150+ Key Companies Shaping the Future of Chronic and Acute Pain Therapeutics | DelveInsight - GlobeNewswire Inc.
Ensysce Flat on Review News - Baystreet.ca
Opioid designed to stay inactive until swallowed hits Phase 3 milestone - stocktitan.net
Rate Hike: Will The Western Union Company benefit from geopolitical trendsBond Market & Fast Gain Stock Tips - baoquankhu1.vn
Merger Talk: Is Ensysce Biosciences Inc stock showing strong momentumQuarterly Trade Summary & Low Risk Investment Opportunities - baoquankhu1.vn
Ensysce Biosciences receives patent allowance in Brazil for pain tech By Investing.com - Investing.com Canada
Ensysce Biosciences receives patent allowance in Brazil for pain tech - Investing.com
New Brazil patent backs Ensysce bid for safer opioid pain drugs - Stock Titan
Volume Recap: Is Ensysce Biosciences Inc stock dividend yield sustainableTrade Exit Report & Low Risk High Win Rate Picks - Bộ Nội Vụ
Panic Selling: Why Ensysce Biosciences Inc. stock is seen as undervaluedJuly 2025 Big Picture & Detailed Earnings Play Strategies - Bộ Nội Vụ
What sentiment indicators say about Ensysce Biosciences Inc. stockBreakout Watch & Stock Portfolio Risk Management - ulpravda.ru
Ensysce Biosciences Annual Meeting: Share Issuance Approved, PF614 Phase III and FDA Designations Update - Defense World
Why Ensysce Biosciences Inc. stock is seen as undervaluedJuly 2025 Sector Moves & AI Based Trade Execution Alerts - Улправда
Why Ensysce Biosciences Inc. stock could be next big winnerWeekly Trade Report & AI Forecasted Stock Moves - Улправда
Ensysce Biosciences Shareholders Approve Key Corporate Actions - TipRanks
How Ensysce Biosciences Inc. stock compares to growth peersWeekly Gains Report & Safe Capital Growth Stock Tips - Улправда
How rising interest rates impact Ensysce Biosciences Inc. stockJuly 2025 Setups & Daily Technical Forecast Reports - Улправда
Can Ensysce Biosciences Inc. stock resist market sell offsQuarterly Risk Review & Step-by-Step Trade Execution Guides - Улправда
MarketsMedicine Hat News - FinancialContent
New ADHD drug designed to deter abuse and overdose wins EU patent - Stock Titan
How Ensysce Biosciences Inc. stock reacts to Fed rate cutsSell Signals and Alerts & Low Cost Trading Plans - Улправда
Ensysce Biosciences, Inc.Common Stock (NQ: ENSC - FinancialContent
ENSC: All proposals passed and clinical programs advanced, setting the stage for a pivotal year - TradingView — Track All Markets
Ensysce’s PF614 Steps Forward in Phase 3 Post-Surgery Pain Trial: What Investors Should Watch - TipRanks
Ensysce Biosciences Issues Annual Shareholder Letter - The Globe and Mail
Ensysce Biosciences advances phase 3 trial for abuse-resistant opioid By Investing.com - Investing.com India
Ensysce Biosciences advances phase 3 trial for abuse-resistant opioid - Investing.com
Inside a biotech developing pain pills with built-in overdose protection - Stock Titan
Ensysce Biosciences Secures $4M Financing for PF614 - MSN
Ensysce Biosciences, Inc. (NASDAQ:ENSC) Short Interest Up 188.9% in December - Defense World
Will Ensysce Biosciences Inc. stock maintain growth storyWeekly Profit Recap & Free Community Supported Trade Ideas - Улправда
Ensysce Biosciences’ Innovative Approach to Safer Opioid Use: A Clinical Study Update - MSN
Why Ensysce Biosciences Inc. stock is considered a top pick2025 Trading Volume Trends & Weekly Stock Breakout Alerts - Улправда
How buybacks impact Ensysce Biosciences Inc. stock valueEarnings Performance Report & Community Shared Stock Ideas - Улправда
Can Ensysce Biosciences Inc. stock maintain operating margins2025 AllTime Highs & Verified Stock Trade Ideas - Улправда
Resistance Check: Can Ensysce Biosciences Inc. stock maintain operating marginsMarket Performance Report & High Return Trade Guides - Улправда
Ensysce Biosciences Earnings Notes - Trefis
EBIT per share of Ensysce Biosciences Inc. – OTC:ENSCW - TradingView — Track All Markets
Finanzdaten der Ensysce Biosciences Inc-Aktie (ENSC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):